Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

65
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
65
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

68
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

112
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
112
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

180
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
180
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

118
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
118
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

98
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
98

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

scRNA-seq based gene and cell dynamics behind the formation of the non-caseating granulomas.

Computational biology and chemistry·2026
Same author

Design, Synthesis, and Biological Evaluation of Tetrahydropyridine Analogues as Potent Antibiofilm Agents against <i>S. aureus</i>: In Vitro and In Silico Studies.

ACS omega·2026
Same author

Metatranscriptomics: A Tool for Clinical Metagenomics.

Omics : a journal of integrative biology·2024
Same author

A metagenome-wide association study of gut microbiome in patients with AMD, ASD, RA, T2D & VKH diseases.

Computational biology and chemistry·2024
Same author

<i>In-silico</i> mining to glean SNPs of pharmaco-clinical importance: an investigation with reference to the Indian populated SNPs.

In silico pharmacology·2023
Same author

Identification and annotation of milk associated genes from milk somatic cells using expression and RNA-seq data.

Bioinformation·2023
Same journal

Predicting piRNA-Disease Associations Based on Dual-View Learning and Multi-head Self-Attention Mechanism Fusion.

Interdisciplinary sciences, computational life sciences·2026
Same journal

DTANet+: Dual Interaction and Kernel-Diverse Network for Drug-Target Affinity Prediction.

Interdisciplinary sciences, computational life sciences·2026
Same journal

STNMAE: Identifying Spatial Domains from Spatial Transcriptomics Data with Neighbor-Aware Multi-view Masked Graph Autoencoder.

Interdisciplinary sciences, computational life sciences·2026
Same journal

Diagnosis and Prediction of Alzheimer's Disease via a High-Level Convolutional Block Attention Module-Residual Network.

Interdisciplinary sciences, computational life sciences·2026
Same journal

Deep3D-DTA: A Tri-Modal Deep Learning Framework for Binding Affinity Prediction Leveraging 3D Structural Representations of Drugs and Targets.

Interdisciplinary sciences, computational life sciences·2026
Same journal

ST-LDAW: A Topic-Model and Damped Weighted Least-Squares Method for Integrative Deconvolution of Single-Cell and Spatial Transcriptomics.

Interdisciplinary sciences, computational life sciences·2026
See all related articles

Related Experiment Video

Updated: Apr 5, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.6K

TPMT Polymorphism: When Shield Becomes Weakness.

Pramod Katara1, Himani Kuntal2

  • 1Center of Bioinformatics, University of Allahabad, Allahabad, India. pmkatara@gmail.com.

Interdisciplinary Sciences, Computational Life Sciences
|August 23, 2015
PubMed
Summary
This summary is machine-generated.

Genetic variations in Thiopurine methyltransferase (TPMT) affect how patients metabolize thiopurine drugs, increasing risks for some. Understanding TPMT polymorphism is key to personalized medicine and avoiding adverse drug reactions.

Keywords:
DrugMetabolismPolymorphismThiopurine methyl transferaseVariable drug response

More Related Videos

Genotyping Single Nucleotide Polymorphisms in the Mitochondrial Genome by Pyrosequencing
07:24

Genotyping Single Nucleotide Polymorphisms in the Mitochondrial Genome by Pyrosequencing

Published on: February 10, 2023

2.1K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K

Related Experiment Videos

Last Updated: Apr 5, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.6K
Genotyping Single Nucleotide Polymorphisms in the Mitochondrial Genome by Pyrosequencing
07:24

Genotyping Single Nucleotide Polymorphisms in the Mitochondrial Genome by Pyrosequencing

Published on: February 10, 2023

2.1K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K

Area of Science:

  • Pharmacogenomics
  • Drug Metabolism
  • Biochemistry

Background:

  • Thiopurine methyltransferase (TPMT) is a crucial enzyme in the phase II metabolic pathway.
  • It metabolizes thiopurine drugs (e.g., azathioprine, 6-mercaptopurine) used for cancer, autoimmune diseases, and transplants.
  • TPMT genetic polymorphism influences drug efficacy and can lead to severe adverse reactions.

Purpose of the Study:

  • To review the distribution of TPMT variants across ethnic groups.
  • To discuss the associated risks of adverse drug reactions (ADRs).
  • To explore strategies for mitigating these risks, including personalized medicine.

Main Methods:

  • Literature review of pharmacogenomic studies on TPMT.
  • Analysis of TPMT variant distribution in different populations.
  • Discussion of clinical implications and drug development strategies.

Main Results:

  • Significant ethnic variations exist in TPMT genetic polymorphism.
  • Individuals with TPMT variants face a higher risk of severe toxicity from thiopurine drugs.
  • Understanding these variants is critical for safe and effective drug use.

Conclusions:

  • TPMT genetic polymorphism is a significant factor in thiopurine drug response.
  • Personalized medicine approaches, considering TPMT status, are essential for patient safety.
  • Further research into TPMT variants can inform drug design and treatment protocols.